Inpharma Weekly

, Volume 1215, Issue 1, pp 6–7 | Cite as


a vital role in breast cancer disease management
  • Amanda Cameron
Newsletter Article


When choosing which disease management programmes to fund, health maintenance organisations must consider both the needs of its membership and the realities of economic survival - what is good for patients is not necessarily good for the bottom-line. In the case of breast cancer, a programme encouraging the use of the hormonal drug tamoxifen would provide clear benefits for women since the agent has been shown to reduce the risk of breast cancer by 49%. But what about the cost of such a programme? Researchers at the 4th Annual Disease Management Congress [ Boston, Massachusetts, US; October 1999 ] presented data examining the cost of breast cancer in two managed-care populations and the impact of a breast cancer risk management programme.


Breast Cancer Tamoxifen Breast Cancer Risk Disease Management Programme Health Maintenance Organisation 

Copyright information

© Adis International Ltd 1999

Authors and Affiliations

  • Amanda Cameron

There are no affiliations available

Personalised recommendations